Human | MAGED4B | 81557 | melanoma antigen family D, 4B | Finally, this study indicates that serous cystadenocarcinomas may be suitable tumours for MAGE-1 peptide immunotherapy. A total of 15/27 malignant specimens expressed MAGE-1, including 10/14 serous cystadenocarcinomas. |
Human | PRAME | 23532 | preferentially expressed antigen in melanoma | the 4 biomarkers CLU, ITGB3, PRAME and CAPG may be used as prognostic factors for patients with stage III serous ovarian adenocarcinomas |
Human | IGF2BP3 | 10643 | insulin-like growth factor 2 mRNA binding protein 3 | Expression of IMP3 and p53 may be helpful biomarkers in the distinction of endometrial serous carcinoma from endometrioid adenocarcinoma |
Human | SRA1 | 10011 | steroid receptor RNA activator 1 | Upregulation of steroid receptor RNA activator is associated with serous Cystadenocarcinoma of the ovary |
Human | MBD2 | 8932 | methyl-CpG binding domain protein 2 | We also identified a weak trend indicating that dMTase expression may occur more frequently in cases of endometrioid and serous adenocarcinoma. |
Human | ENDOU | 8909 | endonuclease, polyU-specific | In serous cystadenocarcinomas, SP1 was present in 35.0% of cases, PP5 in 76.2%, PP10 in 9.5%, PP11 in 57.1% and PP12 in 23.8%. |
Human | ABCC3 | 8714 | ATP-binding cassette, sub-family C (CFTR/MRP), member 3 | CONCLUSIONS: In patients with advanced ovarian serous papillary adenocarcinoma, these results suggest that patients with an unfavorable clinical outcome are characterized by increased levels of coordinated MRP1 and MRP3 mRNA expression in their tumor samples. EXPERIMENTAL DESIGN: We examined tumor samples taken from 30 patients with primary serous papillary adenocarcinoma of the ovary for the expression of MDR1 and MRP1, MRP2, and MRP3 mRNA by using real-time reverse transcription-PCR, and we evaluated its correlation with clinical outcome. |
Human | BARX2 | 8538 | BARX homeobox 2 | We have previously shown that BARX2 expression is low in clear cell/endometrioid and high in serous adenocarcinomas of the ovary, histologic variants that are less and more sensitive, respectively to platinum chemotherapy. |
Human | HMGA2 | 8091 | high mobility group AT-hook 2 | Active expression of HMGA2 found in serous carcinoma of ovarian epithelial cells |
Human | TFPI2 | 7980 | tissue factor pathway inhibitor 2 | In serous cystadenocarcinomas, SP1 was present in 35.0% of cases, PP5 in 76.2%, PP10 in 9.5%, PP11 in 57.1% and PP12 in 23.8%. |
Human | TRIM25 | 7706 | tripartite motif containing 25 | CONCLUSION.: The expression of Efp was detected in human epithelial ovarian cancer and high expression of Efp was correlated with advanced disease and serous adenocarcinoma, and ERs status. Efp expression was significantly higher in a subgroup with serous adenocarcinoma (P = 0.010) and with advanced disease (P = 0.026). |
Human | VEGFA | 7422 | vascular endothelial growth factor A | Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage |
Human | TP53 | 7157 | tumor protein p53 | The p53 genotype distribution was markedly different between the ovarian mucinous cystadenocarcinomas and serous papillary cystadenocarcinomas with respect to homozygosity of both Arg and Pro Genetic alterations of the p53 tumor suppressor gene were seen in a mixed serous carcinoma of the endometrium |
Human | TNF | 7124 | tumor necrosis factor | Significantly higher tumor necrosis factor-alpha expression levels are associated with serous adenocarcinoma |
Human | TIMP2 | 7077 | TIMP metallopeptidase inhibitor 2 | METHODS: MMP-2, MMP-2 activator, MT1-MMP, and its inhibitor (TIMP-2) were immunostained in 84 primary epithelial ovarian carcinomas (EOCs) (35 endometrioid adenocarcinomas [ECs] and 49 serous adenocarcinomas [SCs]). |
Human | TIMP1 | 7076 | TIMP metallopeptidase inhibitor 1 | RESULTS: Concentrations of MMP-9 and MMP-2 were statistically higher in serous adenocarcinomas than in serous adenomas (p < 0.01, p < 0.05, respectively), while the concentrations of TIMP-1 and TIMP-2 showed no significant difference between adenocarcinomas and adenomas. |
Human | SLC2A1 | 6513 | solute carrier family 2 (facilitated glucose transporter), member 1 | GLUT1 is expressed in the vast majority of endometrial intraepithelial and uterine serous papillary carcinoma, suggesting a biological role during the early steps of carcinogenesis in endometrial serous neoplasms |
Human | PTGS2 | 5743 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | expression of COX-2 may be induced in serous ovarian carcinomas by loss of tumor suppressor genes such as p53 and SMAD4 and by amplification of HER-2/neuoncogene Serous cystadenocarcinomas also had an unexpectedly high expression of COX-2 |
Human | KLK10 | 5655 | kallikrein-related peptidase 10 | Kallikrein 10 is highly expressed in uterine serous papillary carcinoma, and it is released in the plasma and serum of uterine serous papillary carcinoma patients |
Human | KLK6 | 5653 | kallikrein-related peptidase 6 | Kallikrein 6 is highly expressed in uterine serous papillary carcinoma (USPC) and is released in the plasma and serum and may represent a novel biomarker for USPC for monitoring early disease recurrence and response to therapy |
Human | OVGP1 | 5016 | oviductal glycoprotein 1, 120kDa | Of 183 serous adenocarcinomas, 26 (14%) were positive for OGP, including 5 of 8 (63%) grade I, 7 of 41 (17%) grade II, and 14 of 134 (10%) grade III carcinomas. |
Human | NME1 | 4830 | NME/NM23 nucleoside diphosphate kinase 1 | METHODS: In this study 20 serous cystadenocarcinomas, ten borderline and five benign tumours were analysed for expression of the nm23 antimetastasis gene by immunohistochemistry and for numerical chromosomal abnormalities of chromosomes 1 and 17 by interphase cytogenetics. |
Human | CEACAM6 | 4680 | carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) | It was established that: 1) ovarian mucinous and serous adenocarcinomas are immunologically different and possess various tumor-associated antigens, 2) ovarian mucinous adenocarcinomas contain considerable amounts of CEA and NCA, whereas serous type neoplasms show negligible amounts or lack of these antigens; and 3) in both types of tumors, alpha-1-antichymotrypsin and alpha-1-acid glycoprotein activities are found. |
Human | MN1 | 4330 | meningioma (disrupted in balanced translocation) 1 | We examined the expression of BMP-2 and typle IV collagen by immunohistochemistry and reverse transcription PCR (RT-PCR) in PBs-forming (NK-211) and -non-forming (SHIN-3, KF-1, A2780, KK-92, KOC-2S, SKOV-3, OMC-3, MN-1, EC, and KEN-3) ovarian cancer cell lines in vitro and in surgical specimens of serous adenocarcinoma (SA) with/without PBs and mucinous adenocarcinoma (MA) of the ovary. |
Human | MCM2 | 4171 | minichromosome maintenance complex component 2 | Sections of normal ovary (n=18), serous cystadenoma (n=21), borderline serous tumours (n=21) and serous cystadenocarcinoma (n=15) were analysed by immunohistochemistry using markers of cell cycle entry (Mcm-2) and cell cycle phase, including cyclin D1 (mid-to-late G1), cyclin A (S phase), cyclin B1 (G2 phase) and phosphohistone H3 (mitosis). |